Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series

被引:1
|
作者
Weinstock, Leonard B. [1 ]
Nelson, Renee M. [2 ]
Blitshteyn, Svetlana [2 ,3 ]
机构
[1] Gastroenterology, St Louis, MO 63141 USA
[2] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurol, Buffalo, NY 14203 USA
[3] Dysauton Clin, Williamsville, NY USA
来源
JOURNAL OF PERSONALIZED MEDICINE | 2023年 / 13卷 / 11期
关键词
anxiety; depression; dysautonomia; mast cell activation syndrome; panic disorder; POTS; HISTAMINE; MASTOCYTOSIS; DISEASE; MECHANISMS; SYMPTOMS; RELEASE; ANXIETY;
D O I
10.3390/jpm13111562
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Mast cell activation syndrome (MCAS) is an immune disease with an estimated prevalence of 17%. Mast cell chemical mediators lead to heterogeneous multisystemic inflammatory and allergic manifestations. This syndrome is associated with various neurologic and psychiatric disorders, including headache, dysautonomia, depression, generalized anxiety disorder, and many others. Although MCAS is common, it is rarely recognized, and thus, patients can suffer for decades. The syndrome is caused by aberrant mast cell reactivity due to the mutation of the controller gene. A case series is presented herein including eight patients with significant neuropsychiatric disorders that were often refractory to standard medical therapeutics. Five patients had depression, five had generalized anxiety disorder, and four had panic disorder. Other psychiatric disorders included attention-deficit hyperactivity disorder, obsessive compulsive disorder, phobias, and bipolar disorder. All eight patients were subsequently diagnosed with mast cell activation syndrome; six had comorbid autonomic disorders, the most common being postural orthostatic tachycardia syndrome; and four had hypermobile Ehlers-Danlos syndrome. All patients experienced significant improvements regarding neuropsychiatric and multisystemic symptoms after mast-cell-directed therapy. In neuropsychiatric patients who have systemic symptoms and syndromes, it is important to consider the presence of an underlying or comorbid MCAS.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] CASE SERIES OF SUSPECTED MAST CELL ACTIVATION SYNDROME IN THREE PATIENTS
    Jongco, A. M.
    Cavuoto, M.
    Bonagura, V. R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A55 - A55
  • [2] An Unusual Case of Mast Cell Activation Syndrome
    Patel, R.
    Celestin, J.
    Frieri, M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB125 - AB125
  • [3] Mast cell activation syndrome: Review of a case
    Gonzalez-Afonso, M.
    Martinez-Tadeo, J. A.
    Mendoza-Alvarez, A.
    Perez-Rodriguez, E.
    Garcia Robaina, J. C.
    ALLERGY, 2023, 78
  • [4] OMALIZUMAB IN TREATMENT OF MAST CELL ACTIVATION SYNDROME
    Brown, R.
    Yao, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S86 - S87
  • [5] MAST CELL ACTIVATION SYNDROME AND MANAGEMENT OF ITS PROTEAN MANIFESTATIONS
    Hakim, M.
    Kurian, D.
    Rehman, U.
    Kazmi, S.
    Ghazi, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S49 - S49
  • [6] Mast cell activation syndrome
    Vacheron, Nathalie
    McClinton, Tracy
    Lynch-Smith, Donna J.
    Umberger, Reba
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2021, 33 (07) : 545 - 552
  • [7] Mast Cell Activation Syndrome
    Frieri, Marianne
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2018, 54 (03) : 353 - 365
  • [8] Mast cell activation syndrome
    Ratner, Vicki
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (05) : 587 - 588
  • [9] Mast cell activation syndrome
    Brockow, K.
    HAUTARZT, 2013, 64 (02): : 102 - 106
  • [10] Mast Cell Activation Syndrome
    Marianne Frieri
    Clinical Reviews in Allergy & Immunology, 2018, 54 : 353 - 365